NCT03198130 - An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

June 27, 2019

Study Completion Date

February 21, 2020

Conditions

Recurrent Squamous Cell Carcinoma of HeadRecurrent Squamous Cell Carcinoma of NeckMetastatic Squamous Cell Carcinoma of HeadMetastatic Squamous Cell Carcinoma Neck

Interventions

DRUG

REGN2810

Intravenous (IV) use

Trial Locations (6)

03080

Seoul National University, Seoul

03722

Yonsei University College of Medicine, Severence Hospital, Seoul

06351

Samsung Medical Center, Seoul

Unknown

University Birmingham, Birmingham

Guy's and St. Thomas' NHS Foundation Trust, London

Royal Cancer Hospital, London